Transmembrane protein C16orf54 (SAIL) (SAIL)

Transmembrane protein C16orf54, also known as Surface Antigen In Leukemia (SAIL), is a cell-surface protein that has emerged as a promising therapeutic target for hematological malignancies, including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) [3, 4, 7]. It is characterized by high expression on malignant cells and restricted expression in normal tissues such as the bone marrow and lymph nodes, providing a favorable therapeutic window for targeted agents [1, 7, 11]. C16orf54 is implicated in the modulation of the tumor immune microenvironment, where its expression levels correlate with immune cell infiltration and tumor stemness across various cancers [1, 5]. Therapeutic strategies targeting this molecule primarily involve antibody-drug conjugates (ADCs), such as IGN786 and auristatin-based conjugates (e.g., 7-1C), which utilize the protein's surface localization to deliver potent cytotoxic payloads directly to tumor cells [4, 7, 11]. Additionally, C16orf54 serves as a potential prognostic and diagnostic biomarker, with its expression linked to cytokine receptor interactions and T-cell signaling pathways [1, 5, 12]. The protein's role in immune signaling and its presence on the surface of leukemic stem cells make it a focal point for developing next-generation immunotherapies [4, 14]. Clinical development has focused on leveraging its unique expression profile to overcome the limitations of conventional chemotherapy in resistant hematological cancers [7, 11].

Other names

Surface Antigen In LeukemiaC16orf54Chromosome 16 open reading frame 54FLJ35681UNQ9389/PRO34280

Antibody-drug conjugate (ADC) mediated delivery of cytotoxic payloads to SAIL-expressing cells [4, 7, 11]